| 赵丹青,王苏,张婧婧,胡斌,魏晨敏,左志华.度拉糖肽联合骨化三醇治疗2型糖尿病合并骨质疏松症患者的效果及对骨代谢指标的影响[J].中国临床保健杂志,2023,26(6):771-774. |
| 度拉糖肽联合骨化三醇治疗2型糖尿病合并骨质疏松症患者的效果及对骨代谢指标的影响 |
| Effect of dulaglutide combined with calcitriol on curative effebone metabolism in patients with T2DM complicated with osteoporosis |
| 投稿时间：2023-10-22 |
| DOI：10.3969/J.issn.1672-6790.2023.06.012 |
| 中文关键词: 糖尿病,2型 骨质疏松 骨化三醇 二甲双胍 骨密度 |
| 英文关键词: Diabetes mellitus,type 2 Osteoporosis Calcitriol Metformin Bone density 〖FL |
| 基金项目:江苏省中医药管理局科技项目(JD2019SZXYB08) |
|
| 摘要点击次数: 130 |
| 全文下载次数: 158 |
| 中文摘要: |
| 目的 探讨度拉糖肽联合骨化三醇治疗2型糖尿病(T2DM)合并骨质疏松症患者的效果。方法 选取2019年8月至2021年8月南京市江宁医院门诊T2DM合并骨质疏松症女性患者120例,按照随机数字表法分为对照组、研究组,各60例。2组均给予基础治疗干预,对照组采用二甲双胍联合骨化三醇治疗,研究组采用度拉糖肽联合二甲双胍及骨化三醇治疗。比较2组治疗1年后疗效,对比治疗前、治疗1年后血糖水平[空腹血糖(FBG)、餐后2 h血糖(2 hPG)、糖化血红蛋白(HbA1c)、体重指数(BMI)]、骨密度(股骨颈、L1-4、全髋)及骨代谢指标[碱性磷酸酶(ALP)、β-1型胶原羧基末端肽(β-CTX)],统计治疗期间不良反应。结果 研究组总有效率(98.33%)高于对照组(85.00%),P＜0.05；治疗1年后2组FBG、2 hPG、HbA1c、BMI水平低于治疗前,且研究组低于对照组(P＜0.05)；2组骨密度治疗1年后与治疗前相比均升高,且对照组低于研究组(P＜0.05)；2组治疗1年后ALP高于治疗前,β-CTX低于治疗前,且研究组ALP高于对照组,β-CTX低于对照组(P＜0.05)；2组不良反应发生率比较,差异无统计学意义(P＞0.05)。结论 度拉糖肽联合骨化三醇治疗T2DM合并骨质疏松症疗效显著,能降低血糖水平,改善骨密度与骨代谢指标。 |
| 英文摘要: |
| Objective To explore the effect of dulaglutide combined with ossified three alcohol on patients with type 2 diabetes mellitus (T2DM) complicated with osteoporosis.Methods A total of 120 female patients with T2DM complicated with osteoporosis were selected from the outpatient department of Nanjing Jiangning Hospital from August 2019 to August 2021,and were divided into the reference group and the experimental group according to random number table method,with 60 cases in each group.Both groups were given basic treatment intervention,and the control group was treated with metformin combined with calcitriol,and the study group was treated with dulaglutide combined with metformin and calcitriol.The curative effects of the two groups after 1 year of treatment were compared After 1 year of treatment,blood glucose levels[fasting blood glucose (FBG),2 h postprandial blood glucose (2 hPG),glycosylated hemoglobin (HbA1c),Body mass index (BMI)],bone mineral density (femoral neck,L1-4,total hip) and bone metabolism indexes[alkaline phosphatase (ALP),β-Carboxy terminal peptide of type 1 collagen(β-CTX)]were recorded,and adverse reactions during treatment were counted.Results The total effective rate (98.33%) of the experimental group was higher than that of the reference group (85.00%),P<0.05.After 1 year of treatment,the levels of FBG,2 hPG,HbA1c and BMI in the two groups were lower than those before treatment,and those in the experimental group were lower than those in the reference group (P<0.05).BMD in both groups increased after 1 year of treatment compared with before treatment,and the reference group was lower than the experimental group (P<0.05).After 1 year of treatment,ALP was higher than that before treatment,β-CTX was lower than that before treatment,and ALP in the experimental group was higher than that in the reference group,β-CTX was lower than that in the control group (P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusions Dulaglutide combined with calcitriol is effective in the treatment of T2DM complicated with osteoporosis.It can reduce blood glucose level,improve bone mineral density and bone metabolism. |
|
查看全文
|
| 关闭 |
|
|
|